Ballast Point® Releases Aloha Sculpin® IPA Nationwide
Brewery uses 'Brux Trois' yeast; turns award-winning flagship beer into tropical oasis
Aloha Sculpin IPA features a distinct yeast strain known as Saccharomyces "Bruxellensis" Trois, or Brux Trois, turning the flagship IPA into a tropical oasis with aromas and flavors of guava, mango, and pineapple without any fruit additions. While Belgian yeast strains are known for their clove and banana-like aroma, this strain bears exotic fruit aromas. It also adds a slight haze to the beer, creating a smooth mouthfeel to round out its juicy character.
Not only does this yeast strain add a unique flavor profile to the brew, but its use in Aloha Sculpin marks the first time an IPA brewed with Saccharomyces brux Trois is being packaged and made available nationwide.
"We're always experimenting with new ingredients and methods," said James Murray, vice president of brewing at Ballast Point. "Most brewers tend to experiment with hops for flavor and aroma. But when we tasted the guava, mango and pineapple notes from this yeast in other R&D recipes we brewed, we knew it would really enhance the bright, tropical fruit characteristics already present in Sculpin IPA."
Innovation is a part of Ballast Point's DNA and has been a critical part of the brewery's success dating back to the days of Home Brew Mart. As a pioneer in the San Diego craft beer movement, the brewery currently makes over 50 styles of beer, each with innovation and quality in mind. Experimenting with Brux Trois yeast is a testament to this focus.
"This strain is a bit finicky," said Lauren Zeidler, director of quality at Ballast Point. "It's very particular about what it likes and doesn't, so we had to get to know its preferences and adjust accordingly. It was a unique challenge, but it made the brewing and batch scaling even more of a satisfying accomplishment."
The original Sculpin IPA launched in 2005 and has since become the hallmark of the west coast-style IPA, winning gold medals at the World Beer Cup (2010, 2014) and European Beer Star (2010, 2011). Years later, the Sculpin family has expanded to include Grapefruit, Pineapple, Habanero, Unfiltered - and now Aloha Sculpin.
Aloha Sculpin IPA is a spring/summer seasonal release under Ballast Point's flagship tier and is now rolling out nationwide in both draft and six-pack bottles.
For more information, visit www.BallastPoint.com.
About Ballast Point Brewing Company
Started in 1996 by a small group of home brewers in San Diego, Ballast Point has a 20-plus-year history of supporting the art of home brewing and developing high-quality, innovative and award-winning beer. Ballast Point has become one of the nation's leading craft breweries by exploring new tastes and techniques to create the perfect balance of taste and aroma. At Ballast Point, a culture of quality persists from selection of raw materials to the brewing process to the finished product and beyond. From developing a proprietary yeast for our amber ale to creating a breakthrough gold medal-winning IPA, Ballast Point is dedicated to the craft of brewing beers for all to enjoy.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/35145537-1f86-4c08-9b33-453b9a5a96f8
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ballast Point Brewing Company via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Despite Brexit Uncertainty, Business Schools in UK Continue to See Strong International Demand19.3.2019 09:00:00 CET | Pressemelding
Majority of Candidates Say Brexit has No Impact on Decision to Study in the United Kingdom RESTON, Va., March 19, 2019 (GLOBE NEWSWIRE) -- In response to the initial Brexit vote in June 2016, the Graduate Management Admission Council™ (GMAC™) has been tracking Graduate Management Admission Test™ (GMAT™) examinee interest in studying in the UK. This has included periodic surveys of non-U.K. citizens who sent a GMAT score report to a UK business school program, as an indication of where they are interested in studying. In the immediate aftermath of the vote, it was unclear what the impact would be on the international flow of students to UK programs, which are heavily reliant on enrollees from other countries. Brexit, it’s been feared, could restrict or complicate the student visa process and dampen international candidates’ postgraduation job prospects in the UK, both because of possible changes to work visa policies and jobs leaving the UK. However, the most recent survey findings, fro
General Electric Company: Doc re. GE files DEFA14A19.3.2019 08:00:00 CET | Pressemelding
FAIRFIELD, Conn., March 19, 2019 (GLOBE NEWSWIRE) -- Company ISIN Symbol Headline General Electric Company US3696041033 London: GEC | Paris: GNE Doc re: GE files DEFA14A March 18, 2019 On March 18, 2019, General Electric Company (the "Company") filed a DEFA14A (Definitive Additional Materials) with the U.S. Securities and Exchange Commission ("SEC"), which has been submitted to the U.K. National Storage Mechanism and will be available shortly for inspection at http://www.morningstar.co.uk/uk/NSM. It is also available on the SEC's website at http://www.sec.gov and on the Company's website at https://www.ge.com/investor-relations/events-reports. CONTACT: GE Jennifer Erickson +001 646 682 5620 email@example.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this informatio
General Electric Company: Doc re. GE Files DEF 14A19.3.2019 08:00:00 CET | Pressemelding
FAIRFIELD, Conn., March 19, 2019 (GLOBE NEWSWIRE) -- Company General Electric Company ISIN US3696041033 Symbol London: GEC | Paris: GNE Headline Doc re: GE files DEF 14A March 18, 2019 On March 18, 2019, General Electric Company (the "Company") filed a DEF 14A (Proxy Statement) with the U.S. Securities and Exchange Commission ("SEC"), which has been submitted to the U.K. National Storage Mechanism and will be available shortly for inspection at http://www.morningstar.co.uk/uk/NSM. It is also available on the SEC's website at http://www.sec.gov and on the Company's website at https://www.ge.com/investor-relations/events-reports. CONTACT: GE Jennifer Erickson +001 646 682 5620 firstname.lastname@example.org This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For
Validated with Microsoft Skype for Business, Patton Delivers Cloud-Powered Integration19.3.2019 05:00:00 CET | Pressemelding
SmartNode ™ VoIP gateways and eSBCs, validated by TekVizion, integrate legacy telephony, ALL-IP communications — or both concurrently — with Skype for Business SmartNode ™ VoIP… More than Just Talk! GAITHERSBURG, Md., March 19, 2019 (GLOBE NEWSWIRE) -- Patton—US-based enabling solutions provider for unified communications (UC), UC-as-a-service (UCaaS) and Cloud—now announces all SmartNode VoIP products version 3.X—including Virtual SmartNode (vSN)—are validated for interoperability with Skype for Business (SfB). SmartNode products are validated by TekVizion, a Microsoft-certified lab, in the SBC and enhanced gateway categories, and are forward compatible with Microsoft Teams. >>Certificate of Validation: Patton SBC/Gateway 3.X Patton Cloud edge orchestration service makes it extra easy to activate, configure and manage the SmartNode-enabled connection with on-premise or hosted Skype for Business. In addition to enabling enterprise transition to ALL-IP using SfB, Patton’s VoIP CPE produ
Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results18.3.2019 21:45:00 CET | Pressemelding
On track to initiate Phase 3 VITAL™ trial for treatment of RDEB in mid-2019; EB-101 to be manufactured in-house Manufacturing scaled to support AAV based programs; GMP readiness expected 2H19 Investor conference call on Tuesday, March 19 at 10:00 a.m. ET NEW YORK and CLEVELAND, March 18, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for serious diseases, today announced fourth quarter and full year 2018 financial results, and provided business highlights. The Company will host a conference call on Tuesday, March 19 at 10:00 a.m. ET to discuss fourth quarter and full year results, and to provide business highlights. Interested parties are invited to participate in the call by dialing 844-369-8770 (toll-free domestic) or 862-298-0840 (International) or via webcast at https://www.investornetwork.com/event/presentation/44847. “The diligent work conducted over the past nine months
Novavax Reports Fourth Quarter and Year-End 2018 Financial Results18.3.2019 21:05:00 CET | Pressemelding
Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md., March 18, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2018. “In 2018, we committed to focus on our two lead programs, ResVax™ and Nanoflu™, and reflecting on last year’s activities, I am proud to say we have achieved significant results for both,” said Stanley C. Erck, President and CEO of Novavax, Inc. “Although we were disappointed to miss the primary endpoint of our Prepare trial, ResVax is the first RSV vaccine to demonstrate efficacy for the prevention of RSV disease in a Phase 3 clinical trial. In addition, the successful Phase 2 results for our NanoFlu vaccine provide an opportunity to now confirm with the FDA the use of accelerated approval for licensure. We are now prepared to make meaningful advances on these programs during 2019.” Fourth Quarter 2018 and Subsequent Opera